Pharming Technologies B.V.

Quick facts

Phase 3 pipeline

• recombinant human C1 inhibitor · Immunology
  Recombinant human C1 inhibitor works by replacing a deficient or dysfunctional C1 inhibitor protein to regulate the complement system and prevent excessive inflammation.

Phase 2 pipeline

• i.v. recombinant human C1 inhibitor
• rhC1INH or pdC1INH

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Pharming Technologies B.V. portfolio CI brief
• Pharming Technologies B.V. pipeline updates RSS